loading page

Pirfenidone Use Facts in Fibrotic Diseases: What Do We Know So Far?
  • +3
  • Aldo Torre-Delgadillo,
  • Froylan David Martinez-Sanchez,
  • Sofía Narvaez-Chávez,
  • Mariana Herrera-Islas,
  • Carlos Aguilar-Salinas,
  • Jacqueline Córdova-Gallardo
Aldo Torre-Delgadillo
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Author Profile
Froylan David Martinez-Sanchez
Hospital General Dr Manuel Gea Gonzalez
Author Profile
Sofía Narvaez-Chávez
Hospital General Dr Manuel Gea Gonzalez
Author Profile
Mariana Herrera-Islas
Hospital General Dr Manuel Gea Gonzalez
Author Profile
Carlos Aguilar-Salinas
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Author Profile
Jacqueline Córdova-Gallardo
Hospital General Dr Manuel Gea Gonzalez

Corresponding Author:[email protected]

Author Profile

Abstract

Pirfenidone has evinced noteworthy anti-inflammatory and antifibrotic efficacy in both animal models and in some clinical trials. Its pronounced potential for antifibrotic activity makes pirfenidone a compelling prospect for the treatment of various fibrotic diseases. Pirfenidone has several pleiotropic and anti-inflammatory mechanism of action through different molecular pathways. Consequently, it attenuates multiple inflammatory processes, including the secretion of pro-inflammatory cytokines, apoptosis, and fibroblast activation. Extensively studied for idiopathic pulmonary fibrosis, pirfenidone has exhibited a favorable impact, and represents part of the current treatment for this disease. In similar fibrotic diseases such as interstitial lung disease, myocardial fibrosis, glomerulopathies, aberrant skin scarring, chronic liver disease, and other fibrotic disorders, pirfenidone seems to exert a beneficial effect. Given the growing incidence of chronic fibrotic conditions, pirfenidone emerges as a potential therapeutic option for the management of these patients. Nonetheless, more clinical trials are needed to confirm its therapeutic effect. In this review, we aim to expose the current evidence of pirfenidone's effect in several fibrotic diseases.
05 Feb 2024Submitted to Immunity, Inflammation and Disease
22 Feb 2024Reviewer(s) Assigned
19 May 2024Review(s) Completed, Editorial Evaluation Pending
20 May 2024Editorial Decision: Revise Major
28 May 20241st Revision Received
29 May 2024Submission Checks Completed
29 May 2024Assigned to Editor
29 May 2024Review(s) Completed, Editorial Evaluation Pending
19 Jun 2024Editorial Decision: Accept